title: Antithrombotic agents and invasive procedures--hematologist point of view.
abstract: The management of a patient treated with an antithrombotic agent who requires an invasive procedure remains challenging. There are antidotes neither for the antiplatelet agents nor the new anticoagulants. A good knowledge of basic pharmacology of these drugs and the help of a hematologist within a multidisciplinary approach are essential. The potential interest of laboratory tests and the use of reversal agents, and the transfusion of plasma and platelets will be discussed.
authors.affiliation: Hôpitaux Universitaires de Genève, et UniGe, Suisse, Switzerland. ThomasPierre.Lecompte@hcuge.ch
authors.forename: T P
authors.initials: TP
authors.lastname: Lecompte
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D000931:Antidotes / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests; D016913:Blood Component Transfusion; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D013514:Surgical Procedures, Operative / Q000009:adverse effects*; D013927:Thrombosis / Q000097:blood / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D000931:Antidotes; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors